Leukotrienes (LTs) are proinflammatory lipid mediators synthesized by the conversion of arachidonic acid (AA) to LTA 4 by the enzyme 5-lipoxygenase (5-LO) in the presence of 5-LO-activating protein (FLAP). 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103) is a novel selective FLAP inhibitor in development for the treatment of respiratory conditions such as asthma. In a rat ex vivo whole-blood calcium ionophore-induced LTB 4 assay, AM103 (administered orally at 1 mg/kg) displayed Ͼ50% inhibition for up to 6 h with a calculated EC 50 of ϳ60 nM. When rat lung was challenged in vivo with calcium ionophore, AM103 inhibited LTB 4 and cysteinyl leukotriene (CysLT) production with ED 50 values of 0.8 and 1 mg/kg, respectively. In this model, the EC 50 derived from plasma AM103 was ϳ330 nM for inhibition of both LTB 4 and CysLT. In an acute inflammation setting, AM103 displayed dose-dependent inhibition of LTB 4 , CysLT, and plasma protein extravasation induced by peritoneal zymosan injection. In a model of chronic lung inflammation using ovalbumin-primed and challenged BALB/c mice, AM103 reduced the concentrations of eosinophil peroxidase, CysLTs, and interleukin-5 in the bronchoalveolar lavage fluid. Finally, AM103 increased survival time in mice exposed to a lethal intravenous injection of platelet-activating factor. In summary, AM103 is a novel, potent and selective FLAP inhibitor that has excellent pharmacodynamic properties in vivo and is effective in animal models of acute and chronic inflammation and in a model of lethal shock.
reaction occurs to convert AA to LTA 4 . LTA 4 can be exported from the cell for transcellular metabolism or converted to either LTB 4 by LTA 4 hydrolase or LTC 4 by LTC 4 synthase. LTC 4 is exported from cells and converted to LTD 4 by ␥-glutamyl transpeptidase and then to LTE 4 by dipeptidases in blood. LTC 4 , LTD 4 , and LTE 4 are collectively referred to as cysteinyl leukotrienes (CysLTs). Inhibition of either FLAP or 5-LO results in inhibition of all LT production.
LTs exert their biological actions by binding to and activating the cell surface of G protein-coupled receptors (GPR). LTB 4 activates two receptors, BLT 1 and BLT 2 , and is a potent mediator of neutrophil chemotaxis, which contributes to innate immunity (Ford-Hutchinson et al., 1980) . CysLTs bind CysLT 1 and CysLT 2 receptors. CysLT 1 -receptor activation leads to bronchoconstriction, airway cell recruitment, and microvascular edema, whereas CysLT 2 -receptor activation can cause endothelial cell cytokine production. A third receptor, GPR17, can be activated by LTC 4 and LTD 4 and may be involved in ischemia-induced tissue injury (Ciana et al., 2006; Pugliese et al., 2009) . In a more recent report, GPR17 was shown to regulate CysLT 1 -receptor responses to LTD 4 but was not directly activated by LTD 4 (Maekawa et al., 2009) . Finally, the P2Y 12 receptor has also been shown to bind LTE 4 with high affinity (Nonaka et al., 2005) .
Studies using genetically engineered mice and selective pharmacological agents have been important for understanding the role of LTs in settings of acute and chronic inflammation. Under acute conditions, FLAP knockout mice (which produce no detectable LTs) show reduced edema and vasopermeability in response to topical AA, reduced protein extravasation in response to peritoneal zymosan, and increased survival in response to a lethal injection of plateletactivating factor (PAF) (Byrum et al., 1997) . The effect of LTs on zymosan-induced extravasation was later shown to involve signaling through the CysLT 1 receptor (Maekawa et al., 2002) . 5-LO-deficient mice were also resistant to PAF lethality (Goulet et al., 1994) . In a more chronic setting, these mice displayed reduced vascular inflammation and decreased incidence of aortic aneurysms, suggesting that LTs may promote vascular diseases including atherosclerosis (Zao et al., 2004) . In pharmacological studies, the FLAP inhibitor MK-886 (Gillard et al., 1989) reduced mucus production and decreased airway eosinophilia in a mouse ovalbumin (OVA) model of allergic asthma, whereas a more potent FLAP inhibitor, MK-591, inhibited bronchoconstriction induced by Ascaris antigen (Frenette et al., 1999) . The 5-LO inhibitor zileuton (ZYFLO; Cornerstone Therapeutics Inc., Cary, NC) was also effective against antigen challenge, leading to reduced neutrophil influx and interleukin (IL)-6 production in the bronchoalveolar lavage (BAL) fluid of monkeys challenged with Ascaris antigen (Turner et al., 1996) . In addition, oral administration of montelukast (Singulair, a CysLT 1 receptor-selective antagonist; Merck & Co., Inc., Whitehouse Station, NJ) blocked LTD 4 -induced bronchoconstriction in conscious squirrel monkeys and OVA-induced bronchoconstriction in conscious-sensitized rats (Jones et al., 1995) . These findings and a large number of other animal and clinical studies support the development of drugs that affect the LT pathway in chronic diseases of pulmonary and vascular inflammation.
Only one LT synthesis inhibitor, namely the 5-LO inhibitor zileuton, is a marketed drug. In addition, a number of CysLT 1 -receptor antagonists, including montelukast, are approved for treatment of asthma and allergic rhinitis. Three FLAP inhibitors have been evaluated in human clinical trials, including MK-866 (Friedman et al., 1993) , MK-591 (Diamant et al., 1995) , and BAYX-1005 (Hamilton et al., 1997) , and all showed efficacy against the early and late phases of allergen-induced lung-volume decline. Although none of these FLAP inhibitors is marketed, MK-591 was efficacious in chronic asthma (Young, 1999) .
3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM103) (Fig. 1) is a novel, potent, and selective FLAP inhibitor with IC 50 values of 350, 113, and 117 nM against human, rat, and mouse whole-blood ionophorestimulated LTB 4 production, respectively, and is in development for the treatment of respiratory conditions such as asthma. In this study, we report the in vivo pharmacodynamic and pharmacological properties of AM103 by using rat and mouse models of acute and chronic inflammation.
Materials and Methods
Animals. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250 to 300 g were used for ex vivo and in vivo ionophorechallenge studies as well as peritoneal zymosan studies. Female CD-1 mice (Harlan) weighing 20 to 25 g were used in PAF experiments, and female BALB/c mice (Harlan) weighing 19 to 22 g were used in the OVA procedure. All animals were given free access to standard rat/mouse chow and water and were allowed to acclimate for 1 week before study initiation. Rats and mice were subject to a 12-h light/dark schedule with lights on at 6:00 AM. All experiments were conducted during the light phase of the light/dark cycle. All procedures were approved by the local Institutional Animal Care and Use Committee.
Drug Solutions. For all experiments, AM103 (synthesized at Amira Pharmaceuticals) was prepared as a uniform suspension in 0.5% methyl cellulose and administered orally in a volume of 3 ml/kg (rat) or 10 ml/kg (mouse). MK-886 (synthesized at Amira Pharmaceuticals) was prepared in 0.5% methyl cellulose. Dexamethasone (Sigma-Aldrich, St. Louis, MO) was prepared in 25% ␤-cyclodextran and dosed orally. In each case, animals were subject to a 16-to 24-h fast before dosing. Sodium pentobarbital (Sigma-Aldrich) was prepared in saline and dosed intraperitoneally.
Human, Rat, and Mouse Blood LTB 4 -Inhibition Assay. Human blood was taken from consenting volunteers, rat blood was from the male Sprague-Dawley strain, and mouse blood was from the female BALB/c strain. In each case, blood was drawn into heparinized tubes and 150 l of aliquots was added to wells containing 1.5 l of dimethyl sulfoxide (DMSO; vehicle) or 1.5 l of the test compound in DMSO. Samples were incubated for 15 min at 37°C. Two microliters of calcium ionophore A23817 (freshly diluted from a 50 mM DMSO stock to 1.5 mM in Hanks' balanced salt solution) was added, and solutions were mixed and incubated for 30 min at 37°C. Samples were centrifuged at 1500 rpm (ϳ300g) for 10 min at 4°C, plasma was removed, and a 1:100 dilution was assayed for LTB 4 concentration by using an enzyme immunoassay (EIA) (Assay Designs, Ann Arbor, MI). Drug concentrations to achieve IC 50 values of vehicle ionophore-stimulated LTB 4 production were determined by nonlinear regression analysis (GraphPad Prism; GraphPad Software Inc., San Diego, CA) of percentage of inhibition versus log drug concentration.
Counter Screens. Cyclooxygenase-1 human whole-blood assay. jpet.aspetjournals.org vehicle control. Calcium ionophore A23187 was added and incubations were continued for 30 min at 37°C. Incubation mixtures were centrifuged at 1500 rpm for 10 min at 4°C, and aliquots of the plasma were diluted 1:100 with assay buffer and analyzed for thromboxane B 2 by a competitive enzyme immunoassay according to the manufacturer's instructions (Assay Designs).
Cyclooxygenase-2 human whole-blood assay. Human blood was obtained by venipuncture from consenting adult volunteers into heparinized tubes and used within 2 h of draw. Aliquots of fresh blood (150 l) were incubated for 15 min at 37°C with 1 l of AM103 diluted in DMSO or with DMSO alone as a vehicle control. Lipopolysaccharide (Escherichia coli, serotype 0111:B4; Sigma-Aldrich) (100 g/ml final concentration) was added in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich). Incubations were continued for 24 h at 37°C and then centrifuged at 1500 rpm for 10 min at 4°C, and aliquots of the plasma were diluted 1:100 with assay buffer and analyzed for prostaglandin E 2 by a competitive EIA according to the manufacturer's instructions (Assay Designs).
5-LO enzyme assay. Known amounts of AM103 (2 l diluted in DMSO) or DMSO alone were added to 94 l of KPB1 buffer (50 mM K 2 HPO 4 , 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol) containing 0.4 mM CaCl 2 and 0.2 mM ATP in a 1.5-ml Eppendorf tube. 5-LO enzyme (ϳ0.4 units in 1 l) (Cayman Chemical, Ann Arbor, MI) was added and the tubes were mixed briefly. The reaction was initiated by the addition of 3 l of a mixture of 1.4 mM arachidonic acid (40 M final concentration) (BIOMOL Research Laboratories, Plymouth Meeting, PA) and 840 g/ml L-␣-phosphatidylcholine (24 g/ml final concentration) (Type XIII-E; Sigma-Aldrich) in ethanol and incubated at room temperature for 2 min. Reactions were terminated, and the protein was precipitated by the addition of 100 l of ice-cold methanol and incubation on ice for 30 min. Tubes were spun at 10,000g at 4°C for 10 min in an Eppendorf 5417R-refrigerated centrifuge. The supernatant was removed and analyzed for 5(S)-H(p)ETE levels by reverse-phase high-performance liquid chromatography (HPLC).
LTA 4 hydrolase enzyme assay. Human LTA 4 hydrolase enzyme was prepared from human polymorphonuclear (PMN) leukocytes by resuspending a cell pellet of enriched human PMN (Biological Specialty Corporation, Colmar, PA) in 4 volumes of ice-cold buffer containing 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM dithiothreitol, and protease inhibitors (Roche Applied Science, Indianapolis, IN). Cells were sonicated for 20-s bursts four times with cooling in between by using a VirSonic sonicator at power level 10 (VirTis, Gardiner, NY). The cell lysate was centrifuged at 2000 rpm for 10 min at 4°C in the Allegra benchtop centrifuge (Beckman Coulter). The supernatant was further centrifuged at 25,000 rpm for 70 min at 4°C in the Avanti J-30I centrifuge by using the JA-25.50 rotor (Beckman Coulter). The supernatant (cytosolic fraction) was removed, and the protein concentration was determined by using the DC Protein Assay Kit (Bio-Rad, Hercules, CA). LTA 4 methyl ester (Cayman Chemical) was saponified by drying down under N 2 , resuspending in methanol/50% sodium hydroxide (9:1), and incubating at room temperature for 30 min. Known concentrations of AM103 (1 l in DMSO) or DMSO alone were added to 18 l of a buffer containing 278 mM Tris (pH 8) and 2.78 mg/ml BSA (Sigma-Aldrich). Thirty microliters of the human PMN cytosolic fraction was added and incubated at room temperature for 5 min. The reaction was initiated by the addition of the saponified LTA 4 methyl ester (1 l of a 250-M stock; 5 M final concentration), and incubation continued for 10 min at room temperature. Reactions were terminated, and the protein was precipitated by the addition of 100 l of ice-cold methanol and incubation on ice for 30 min. Tubes were spun at 10,000g at 4°C for 10 min in an Eppendorf 5417R-refrigerated centrifuge. The supernatant was removed and analyzed for LTB 4 levels by reverse-phase HPLC.
LTC 4 synthase enzyme assay. Known concentrations of AM103 (1 l in DMSO) or DMSO alone were added to 46 l of a buffer containing 100 mM Hepes (pH 7.4), 20 mM MgCl 2 , and 1 mM glutathione (Sigma-Aldrich) in an 0.5-ml Eppendorf tube. Two microliters of a 1 mg/ml stock of human LTC 4 synthase overexpressed in yeast (Schmidt-Krey et al., 2004 ) (a kind gift from Dr. Y. Kanaoke, Brigham and Women's Hospital, Boston, MA) was added, and the mixture was incubated at room temperature for 5 min. The reaction was initiated by the addition of 1 l of LTA 4 methyl ester (200 g/ml; dried under N 2 and dissolved in methanol) (Cayman Chemical), and incubation continued for 10 min at room temperature. Reactions were terminated, and the protein was precipitated by the addition of 100 l of ice-cold methanol and incubation on ice for 30 min. Tubes were spun at 10,000g at 4°C for 10 min in an Eppendorf 5417R-refrigerated centrifuge. The supernatant was removed and analyzed for LTC 4 levels by reverse-phase HPLC.
12-LO enzyme assay. Known concentrations of AM103 (1 l in DMSO) or DMSO alone were added to 95 l of a buffer containing 1 mM ATP (Sigma-Aldrich), 2 mM CaCl 2 , and 10 M indomethacin (Sigma-Aldrich) in PBS (Invitrogen, Carlsbad, CA). Porcine 12-LO (2 units in 1 l) (Cayman Chemical) was added, and the mixture was incubated for 5 min at room temperature. The reaction was initiated by the addition of 2 l of arachidonic acid (2.5 mM; 50 M final concentration) (BIOMOL Research Laboratories) and continued for 2 min at 37°C. Reactions were terminated, and the protein was precipitated by the addition of 100 l of ice-cold methanol and incubation on ice for 30 min. Tubes were spun at 10,000g at 4°C for 10 min in an Eppendorf 5417R-refrigerated centrifuge. The supernatant was removed and analyzed for 12(S)-H(p)ETE levels by reversephase HPLC.
15-LO enzyme assay. Known concentrations of AM103 (3 l in DMSO) or DMSO alone were added to 600 l of buffer containing 0.1 M sodium borate (pH 9). Soybean 15-LO (600 units in 2 l) (Cayman Chemical) was added, and the mixture was incubated for 5 min at room temperature. The reaction was initiated by the addition of 3 l of arachidonic acid (8 mM; 40 M final concentration) (BIOMOL Research Laboratories). The absorbance at 234 nm was recorded every 10 s for 5 min by using an Ultrospec 2100 pro UV/Vis spectrophotometer (GE Healthcare, Piscataway, NJ).
Rat ex Vivo Ionophore-Challenged LTB 4 Biosynthesis. Rats were dosed with AM103 (1 mg/kg, oral), and blood was collected (300-l aliquots) via a previously implanted jugular vein catheter. Collection times included Ϫ1, 0.5, 2, 4, 6, 8, 12, and 24 h relative to AM103 administration. Each aliquot was divided into two samples and assayed for calcium ionophore-induced LTB 4 production by EIA (Assay Designs) and plasma AM103 concentrations by mass spectrometry.
Rat Lung Ionophore-Challenged LTB 4 and CysLT Biosynthesis. Three hours after oral administration of AM103, rats were placed into an enclosed Plexiglas chamber and exposed to CO 2 for a period of 1 to 2 min or until breathing ceased. They were then removed and blood was taken via a cardiac puncture. Subjects were next placed in a supine position, the trachea was exposed by blunt dissection, and a 7-ml bolus of ice-cold PBS (with 5% DMSO) containing 20 g/ml A23187 was instilled by using a 10-ml syringe equipped with a 20-gauge, blunt needle tip. After a 3-min period, the fluid was withdrawn and mixed with equal parts of ice-cold methanol then centrifuged at 10,000g for 10 min at 4°C. The supernatant was stored at Ϫ40°C until analysis for LTB 4 and CysLT concentrations by EIA from Assay Designs and Cayman Chemical, respectively. To determine the baseline activity of each product, the BAL fluid of two naive animals receiving 7 ml of PBS without A23187 was assayed. Blood was centrifuged at 1450g for 10 min at 4°C, and the plasma was analyzed by mass spectrometry for AM103 concentrations.
Rat Peritoneal Zymosan. Zymosan (10 mg/ml) was prepared as a suspension in saline and was boiled for 1 h then allowed to cool before administration. Evans blue dye (0.3%) was prepared in saline. Four hours after oral dosing of AM103 or MK-886, animals received a single intraperitoneal injection of saline (3 ml) containing zymosan followed immediately by an intravenous injection of Evans blue dye (2 ml). One hour after zymosan injection, rats were euthanized, and the peritoneal cavity was flushed with 10 ml of PBS. Ice-cold methanol was added to the resulting fluid (1:1) and was centrifuged at 1200 rpm for 10 min. Vascular edema was assessed by quantifying the amount of Evans blue dye in the supernatant by using a spectrophotometer (A 610 ). LTB 4 and CysLT concentrations in the supernatant were determined by EIA as described above.
Allergen Sensitization and Challenge Protocol. Mice (female BALB/c, 20 -25 g) were immunized by intraperitoneal injections of OVA (Sigma grade V) complexed with alum (100 g) in a 0.2-ml volume (Imject Alum; Pierce, Rockford, IL) on days 0 and 14. Seven days later (day 21), mice were challenged with OVA intranasally (50 g in 50 l; 25 l/nostril) with the aid of isoflurane anesthesia. Twenty-four hours after intranasal challenge, mice were overdosed with sodium pentobarbital (100 mg/kg in a volume of 0.2 ml), and 4 ϫ 0.3 ml of PBS was instilled via a tracheal catheter. The resulting lavage fluid (ϳ1 ml recovered) was centrifuged at 1200 rpm for 10 min, and the supernatant was removed and split into two aliquots; one aliquot (100 l) was mixed with equal parts ice-cold methanol for analysis of CysLTs, and the remaining fluid was analyzed for IL-5, IL-13, and eosinophil peroxidase (EPO). CysLTs, IL-5, and IL-13 concentrations were determined by EIA. EPO was determined according to the method described by Strath et al. (1985) .
Mouse PAF-Induced Mortality. PAF (Sigma-Aldrich) was prepared as a stock solution (0.3 mg/ml) in 0.5% BSA. All mice were challenged with 30 g of PAF in a volume of 100 l via a tail vein injection 3 h after an oral dose of either vehicle, AM103 or MK-886. Death (determined by cessation of breathing) was then recorded over a period of 2 h. All animals surviving the 2-h test session were euthanized by CO 2 inhalation.
Statistical Analysis. Results are expressed as mean Ϯ S.E.M. (in vivo data) or S.D. (in vitro data). Analyses of data were conducted by using GraphPad Prism software (GraphPad Software Inc.) or SigmaStat 3.1 (Systat Software, Inc., San Jose, CA). The human, rat, and mouse whole-blood IC 50 values were generated by nonlinear regression analysis of the data by using GraphPad Prism. The significant level between groups was determined by either one factor analysis of variance (ANOVA) or by t test. Post hoc comparisons were conducted by Tukey's, Student-Newman-Keuls', or Dunnette's method as indicated where appropriate.
Results
Human, Rat, and Mouse Blood LTB 4 Inhibition and Selectivity. AM103 displayed similar potencies across the three species tested. Average IC 50 values (ϮS.D.) for inhibition of calcium ionophore-induced LTB 4 production from human, rat, and mouse whole blood were 352 Ϯ 86, 156 Ϯ 77, and 82 Ϯ 39 nM, respectively. The IC 50 values for MK-886 were 1727 Ϯ 804, 448 Ϯ 141, and 540 Ϯ 188 nM against human, rat, and mouse whole blood, respectively. AM103 was also tested for its ability to inhibit the activity of other enzymes in the AA pathway. AM103 showed little to no inhibition of the 12-or 15-LO enzymes, COX enzymes, LTA 4 hydrolase, or LTC 4 synthase enzymes with IC 50 Ͼ 10 M for each.
Rat ex Vivo LTB 4 Biosynthesis. AM103 administration (1 mg/kg, p.o.) produced a time-dependent inhibition of ex vivo ionophore-challenged whole-blood LTB 4 biosynthesis. Inhibition of 88 Ϯ 3% was observed at the earliest time point of 30 min and peaked at 2 h with 97 Ϯ 1%. A steady decrease was noted over 12 h with no further decrease at 24 h ( Fig.  2A) . The corresponding plasma AM103 concentrations were 1.1 Ϯ 0.1 M at 30 min and 1.9 Ϯ 0.3 M at 2 h (Fig. 2B) . When LTB 4 inhibition is plotted versus plasma AM103 concentration, the calculated EC 50 (the concentration producing 50% inhibition) is 57 nM (Fig. 2C) .
Rat Lung LTB 4 and CysLT Biosynthesis. Calcium ionophore instilled into rat lungs significantly increased BAL fluid LTB 4 concentrations from 0.9 Ϯ 0.08 ng/ml (basal) to 8.1 Ϯ 1.4 ng/ml (Fig. 3A) . Similar results were observed for CysLTs, which increased from 5.5 Ϯ 0.4 ng/ml (basal) to 12.9 Ϯ 2.8 ng/ml (Fig. 3B ). AM103 administered 3 h before ionophore challenge significantly reduced LT production in a dose-dependent manner. The inhibition of BAL LTB 4 by AM103 was Ϫ6, 66, 97, and 98% at doses of 0.3, 1, 3, and 10 mg/kg, respectively. The inhibition of BAL CysLT was 17, 37, 75, and 76% at doses of 0.3, 1, 3, and 10 mg/kg, respectively. The estimated dose producing a 50% inhibition (ED 50 ) was determined to be 0.8 and 1 mg/kg for LTB 4 and CysLTs, respectively (Fig. 3C) . In a separate experiment, we sought to determine whether basal (nonstimulated) LTs measured in BAL fluid could be inhibited by AM103. A single oral dose of 10 mg/kg produced a modest reduction in both endpoints. LTB 4 decreased from 0.13 Ϯ 0.01 to 0.09 Ϯ 0.01 ng/ml (29% inhibition, P Ͻ 0.05), whereas CysLTs decreased from 2.1 Ϯ 0.5 to 1.4 Ϯ 0.2 ng/ml (33% inhibition, P ϭ 0.2). The remaining component probably reflects LTs produced before drug treatment. The differences in basal concentrations between this experiment and that presented above are considered to be normal experiment-to-experiment variations. Plasma AM103 concentrations increased in a dose-dependent manner and correlated with LT inhibition. After plotting the BAL-LT inhibition versus plasma AM103 concentration, the calculated EC 50 is 330 nM for both LTB 4 and CysLT inhibition (Fig. 3D ). This value is approximately 5-fold higher than the ex vivo rat blood IC 50 of 57 nM, and it probably reflects a concentration gradient of drug from the blood to the lung (i.e., the exposure in the blood may be slightly higher than that in the lung).
Rat Peritoneal Zymosan. Zymosan challenge to the rat peritoneum caused a significant increase in LTB 4 from 0.3 Ϯ 0.01 ng/ml (basal) to 4.6 Ϯ 0.5 ng/ml (Fig. 4A ). CysLT concentrations increased from 4.7 Ϯ 2.6 ng/ml (basal) to 20.6 Ϯ 2.8 (Fig. 4B) . Zymosan also caused plasma protein extravasation as measured by the leakage of intravenously injected Evan's blue dye into the peritoneal cavity. After zymosan challenge, the absorbance of the peritoneal fluid increased from 0.08 Ϯ 0.01 OD (basal) to 0.39 Ϯ 0.05 OD (Fig. 4C ). AM103 at 1 and 10 mg/kg showed significant inhibition of all three endpoints. We also noted inhibition of the peritoneal CysLT concentration with 0.1 mg/kg AM103; however, LTB 4 concentrations and Evan's blue leakage were not inhibited at this dose. Similar to the rat BAL experiments, in this study we sought to determine whether basal (nonstimulated) LTs measured in peritoneal fluid could be inhibited by AM103. A single oral dose of 10 mg/kg produced no decrease in LTB 4 and a very modest reduction in CyLTs. LTB 4 concentrations from vehicle-treated animals were 0.1 Ϯ 0.01 ng/ml and from AM103-treated animals were 0.1 Ϯ 0.01 ng/ml. CysLTs, on the other hand, decreased from 4.5 Ϯ 0.6 to 3.3 Ϯ 0.2 ng/ml (27% inhibition, P ϭ 0.09). The FLAP inhibitor, MK-886, tested at a single dose of 10 mg/kg, reduced LTB 4 and CysLT to a similar extent as a 1 mg/kg dose of AM103. We also noted inhibition of plasma protein extravasation by MK-886, but this effect did not reach statistical significance.
Mouse OVA. Intranasal OVA challenge to OVA-sensitized BALB/c mice caused a significant increase in BAL fluid con- Fig. 3 . AM103 dose-dependently inhibits in vivo lung ionophore-stimulated LTB 4 (A) and CysLT (B) production. Rats were pretreated orally with either vehicle or AM103 as indicated and challenged 3 h later with 20 g of A23187 mixed in 7 ml of PBS instilled into the lungs via the trachea. The resulting BAL fluid was then analyzed by EIA. C, the percentage inhibition of LTB 4 and CysLT was calculated after subtracting the basal activity. D, individual subject data correlating plasma AM103 and LTB 4 or CysLT inhibition. The EC 50 value of 330 nM was generated from the resulting regression line of the data. Data from A, B, and C were generated from 2 to 6 rats per group and expressed as the means Ϯ S.E.M. ##, P Ͻ 0.01, #, P Ͻ 0.05 versus basal (no A23187 group); ‫,ءءء‬ P Ͻ 0.001, ‫,ءء‬ P Ͻ 0.01 and ‫,ء‬ P Ͻ 0.05 versus vehicle group, Tukey's post hoc comparisons after ANOVA.
centrations of CysLTs, EPO, and IL-5. CysLTs increased from 1.6 Ϯ 0.2 to 19.4 Ϯ 3.7 ng/ml; EPO increased from 14 Ϯ 5 to 69 Ϯ 12 ng/ml; and IL-5 increased from 8 Ϯ 0.5 to 21 Ϯ 5 pg/ml (Fig. 5) . Oral dosing of mice with 10 mg/kg q.i.d. AM103 inhibited the increase in all three of these endpoints. Dexamethasone treatment produced similar reductions. There was a trend toward an increase in BAL IL-13 after OVA challenge (from 8 Ϯ 0.6 to 14.3 Ϯ 3 pg/ml after OVA), but this effect did not reach statistical significance. Both AM103 and dexamethasone reduced IL-13, but, again, this effect did not reach statistical significance (P ϭ 0.059, OVA vehicle versus OVA AM103).
Mouse PAF-Induced Death. Administration of PAF to vehicle-treated animals caused mortality in 5 of 6 animals within 2 h of injection in the AM103 experiment (Fig. 6A) and caused mortality in 4 of 5 animals in the MK-886 experiment (Fig. 6B) . This result translates to comparable survival rates of 17% (1 of 6 animals) and 20% (1 of 5), respectively. AM103 at doses of 0.3 and 3 mg/kg given 3 h before PAF produced an improvement in survival resulting in 83% (5 of 6) survival. MK-886 had a more modest effect on survival resulting in 50% (2 of 4) with a dose of 30 mg/kg.
Discussion
LTs are products of the 5-LO pathway characterized as having proinflammatory and bronchoconstrictive properties significantly contributing to asthma (For review, see Drazen et al., 1999; Peters-Golden and Henderson, 2007; Evans et al., 2008) . Compounds that inhibit the production of LTs have demonstrated efficacy in patients with asthma. For example, the 5-LO inhibitor, zileuton, showed progressive improvement on respiratory measures and decreased asthma symptoms over a 4-week period (Israel et al., 1993) . In addition, MK-886 and MK-591, two distinct FLAP inhibitors, prevented LT production and inhibited early and late-phase response to allergen challenge (Friedman et al., 1993; Diamant et al., 1995) . MK-0591 has also shown efficacy in chronic asthma studies (Young, 1999) . Herein, we demonstrate that the novel, small molecule FLAP inhibitor, AM103, inhibits the production of LTs in blood and lung and reduces acute and chronic inflammatory responses in rodent.
In vitro, AM103 demonstrated good potency against inhibition of ionophore-stimulated LTB 4 production in human, rat, and mouse whole blood. This assay was first described by Gresele et al. (1986) and has been used extensively in the development of FLAP as well as 5-LO inhibitors. It has the advantage of more closely mimicking the in vivo situation, where drug binding to serum proteins or other cell membranes may impact potency. In general, a shift in potency to the right is seen when going from membrane binding preparations or washed cell assays to assays in whole blood. This effect has been observed with AM103 because it has an IC 50 of 0.5 nM in a human leukocyte assay containing no serum protein (G. Bain, unpublished observations), which then shifts to an IC 50 of 352 nM in ionophore-challenged LTB 4 in human whole blood. AM103 was highly selective for inhibition of FLAP and showed little to no inhibition (IC 50 values Ͼ 10 M) of 5-LO, 12-LO, 15-LO, COX-1, COX-2, LTA 4 hydrolase, and LTC 4 synthase.
By using ex vivo ionophore-stimulated rat whole-blood LTB 4 production, AM103 displayed greater than 50% inhibition of LTB 4 production for up to 6 h after an oral dose of 1 mg/kg with an EC 50 of 60 nM. This observed potency is similar to the in vitro rat whole-blood IC 50 of 158 nM, suggesting reasonable agreement with the in vitro whole-blood assay.
The LT pathway can be activated in rat lung by application of calcium ionophore directly to this tissue in vivo as described by Smith et al. (1995) and was used here to demonstrate the ability of AM103 to inhibit LT production in this key target tissue. AM103 dose-dependently reduced BAL fluid concentrations of LTB 4 and CysLT in response to calcium ionophore. Plasma AM103 concentrations increased in a dose-dependent manner and correlated with LT inhibition. The estimated EC 50 for both LTB 4 and CysLT in this setting was 330 nM. This value is approximately 5-fold higher than the EC 50 of 60 nM obtained by ex vivo rat whole-blood challenge and probably reflects a drug gradient from blood to lung. Alternatively, this result could reflect activation of different cell types between the blood and the lung. For example, neutrophils are the major producers of LTB 4 in whole blood, whereas alveolar macrophages and mast cells become major contributors to LT production in the naive lung. We have also profiled a number of known 5-LO inhibitors in the whole-blood LTB 4 and BAL-ionophore assays and discovered a somewhat surprising observation. For all the 5-LO inhibitors that we have examined, we see a very large shift in potency (10 -20-fold) between the blood-LTB 4 assay and the BAL-ionophore assay (G. Bain, unpublished observations) . It is not clear whether this effect reflects a difference in chemical structure, whereby the physical properties of the FLAP inhibitors allow them to more readily reach the lung, or whether it reflects something distinct about the protein target (FLAP versus 5-LO). Ongoing efforts in our laboratory are addressing this issue.
Intraperitoneal administration of zymosan to rats induces an acute inflammatory response characterized by increased LT biosynthesis and plasma protein extravasation. These effects in rat are similar to results reported previously after injection of zymosan to mice (Doherty et al., 1985; Rao et al., 1994) . In particular, in response to intraperitoneal zymosan, we observed an increase in the production of LTB 4 and CysLTs and an increase in Evan's blue dye leakage into the peritoneal cavity. Treatment of rats with AM103 suppressed LTB 4 and CysLT production and reduced Evan's blue dye leak. This latter response has been shown to be driven, in part, by CysLTs because 5-LO (Byrum et al., 1999) , FLAP (Byrum et al., 1997) , LTC 4 synthase (Kanaoka et al., 2001) , and CysLT 1 receptor (Maekawa et al., 2002 )-deficient mice all show reduced vascular leakage, whereas LTA 4 hydrolasedeficient mice do not (Byrum et al., 1999) . It is interesting to note that the maximal inhibition of Evans blue dye leakage we observed with AM103 was 50%. This result is consistent with the magnitude of inhibition in 5-LO, FLAP, LTC 4 syn- thase, and CysLT 1 receptor-deficient mice. Complete protection from peritoneal zymosan inflammation requires the inhibition of COX products in addition to LTs (Goulet et al., 1994) . MK-886 was evaluated in the assay as a reference compound, and at a single dose of 10 mg/kg we observed full inhibition of LT production and 35% inhibition of Evans blue dye leakage. These results suggest similar efficacy between MK-886 and AM103 in rat. This finding is not surprising given that the two compounds have similar in vitro potencies in ionophore-challenged rat whole-blood LTB 4 production (448 nM, MK-886 versus 156 nM, AM103). In human whole blood, on the other hand, MK-886 is significantly less potent than AM103 (1727 nM versus 352 nM), which suggests that AM103 may show superior efficacy over MK-886 in human clinical trials. In an OVA model of allergic asthma, we found that AM103 administered orally inhibited BAL-fluid CysLTs, EPO, and IL-5. We saw a trend toward a decrease in IL-13, but this effect did not reach statistical significance. The increase in CysLTs we observed is consistent with previous mouse studies (Henderson et al., 1996; Vargaftig and Singer, 2003) and is also consistent with human allergen challenge (Wenzel et al., 1990) . Elevated CysLT in the lung in response to allergen challenge can cause smooth muscle contraction, increased microvascular permeability, mucus hypersecretion, and eosinophilic inflammation. It is noteworthy that LTC 4 synthase knockout mice show reduced accumulation of eosinophils and lymphocytes as well as decreased goblet cell hyperplasia and mucus production in response to OVA challenge (Kim et al., 2006) . Like the LTC 4 synthase knockout mice, BLT 1 receptor null mice show reduced eosinophilia and reduced hyperplasia of goblet cells. This phenotype was accompanied by reduced concentrations of IgE, IL-5, and IL-13 and reduced airway hyperresponsiveness (Terawaki et al., 2005) . Although LTB 4 is often thought of in the context of innate immunity, data from the BLT-deficient mice suggest that LTB 4 may also contribute to Th2 cell responses. We did not measure LTB 4 in the current experiment but expect AM103 at the dose tested to produce significant inhibition of LTB 4 as was seen for CysLT. We note that dexamethasone reduced BAL CysLTs in our mouse OVA model; however, inhaled steroids do not inhibit BAL CysLTs in humans nor do they decrease bronchial hyperresponsiveness to LTD 4 (Gyllfors et al., 2006) . This result may be unique to the mouse OVA model or could reflect differences in steroid potency after oral administration (e.g., dexamethasone in the mouse study) versus inhaled administration (e.g., fluticasone propionate in humans).
Intravenous injection of PAF induces pulmonary hypertension, increased vascular permeability, and bronchospasm resulting in death (Young et al., 1985) . Previous reports have provided a link between LT production and death in this model of severe shock. For example, survival time was enhanced in gene-deficient mice lacking FLAP, 5-LO, or LTA 4 hydrolase (Goulet et al., 1994; Byrum et al., 1997 Byrum et al., , 1999 . Administration of the FLAP inhibitor, AM103, to mice significantly enhanced survival time over the 2-h observation period with maximal protection at a dose of 0.3 mg/kg. MK-886 was also evaluated and did not show the same degree of protection as AM103. This result may reflect improved potency of AM103 in the mouse whole-blood assay or may reflect differences in mouse pharmacokinetics between the two compounds.
In conclusion, AM103 is a potent and selective FLAP inhibitor that blocks the first committed step in the LT pathway, i.e., 5-LO activation. AM103 is pharmacologically active in vitro and after oral administration to animals in models of acute and chronic inflammation. Furthermore, because AM103 inhibits the formation of both LTB 4 and the CysLTs, AM103 may offer additional clinical benefits over LT-receptor antagonists for the treatment of asthma.
